Patient-recorded outcome to assess therapeutic efficacy in protoporphyria-induced dermal phototoxicity: A proposal

Health and Quality of Life Outcomes

Volumn 8, Issue , 2010, Pages

  Minder, Elisabeth I ^a   Schneider Yin, Xiaoye ^a   Minder, Christoph E ^b  

^a TRIEMLI HOSPITAL   (Switzerland)

^b UNIVERSITY HOSPITAL ZURICH   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; CLINICAL ARTICLE; ERYTHROPOIETIC PROTOPORPHYRIA; HUMAN; INTERRATER RELIABILITY; OUTCOME ASSESSMENT; PHOTOTOXICITY; REPRODUCIBILITY; SKIN PAIN; STRUCTURED QUESTIONNAIRE; SUN EXPOSURE; THERAPY EFFECT; CONTACT DERMATITIS; METHODOLOGY; PAIN ASSESSMENT; QUESTIONNAIRE; STATISTICAL MODEL; VALIDATION STUDY;

DERMATITIS, PHOTOTOXIC; HUMANS; MODELS, STATISTICAL; OUTCOME ASSESSMENT (HEALTH CARE); PAIN MEASUREMENT; PROTOPORPHYRIA, ERYTHROPOIETIC; QUESTIONNAIRES; REPRODUCIBILITY OF RESULTS;

EID: 77954835618     PISSN: None     EISSN: 14777525     Source Type: Journal    
DOI: 10.1186/1477-7525-8-60     Document Type: Article

References (34)

1. Anderson K, Sassa S, Bishop DF, Desnick RJ. Disorders of heme biosynthesis: X-linked sideroblastic anemia and the porphyrias. The Metabolic and Molecular Basis of Inherited Disease 2001, 2991-3062. New York: McGraw-Hill, Scriver CR, Beaugrand M, Sly WS, Valle D, 8.
2. Lecha M, Puy H, Deybach JC. Erythropoietic protoporphyria. Orphanet J Rare Dis 2009, 4:19. 10.1186/1750-1172-4-19, 2747912, 19744342.
3. Whatley SD, Ducamp S, Gouya L, Grandchamp B, Beaumont C, Badminton MN, Elder GH, Holme SA, Anstey AV, Parker M, Corrigall AV, Meissner PN, Hift RJ, Marsden JT, Ma Y, Mieli-Vergani G, Deybach JC, Puy H. C-terminal deletions in the ALAS2 gene lead to gain of function and cause X-linked dominant protoporphyria without anemia or iron overload. Am J Hum Genet 2008, 83:408-414. 10.1016/j.ajhg.2008.08.003, 2556430, 18760763.
4. Lamola AA, Piomelli S, Poh-Fitzpatrick MG, Yamane T, Harber LC. Erythropoietic protoporphyria and lead intoxication: the molecular basis for difference in cutaneous photosensitivity. II. Different binding of erythrocyte protoporphyrin to hemoglobin. J Clin Invest 1975, 56:1528-1535. 10.1172/JCI108234, 333131, 1202083.
5. Piomelli S, Lamola AA, Poh-Fitzpatrick MF, Seaman C, Harber LC. Erythropoietic protoporphyria and lead intoxication: the molecular basis for difference in cutaneous photosensitivity. I. Different rates of disappearance of protoporphyrin from the erythrocytes, both in vivo and in vitro. J Clin Invest 1975, 56:1519-1527. 10.1172/JCI108233, 333130, 1202082.
6. Doss MO, Frank M. Hepatobiliary implications and complications in protoporphyria, a 20-year study. Clin Biochem 1989, 22:223-229. 10.1016/S0009-9120(89)80081-5, 2736774.
7. Holme SA, Anstey AV, Finlay AY, Elder GH, Badminton MN. Erythropoietic protoporphyria in the U.K.: clinical features and effect on quality of life. Br J Dermatol 2006, 155:574-581. 10.1111/j.1365-2133.2006.07472.x, 16911284.
8. Minder EI, Schneider-Yin X, Steuer J, Bachmann LM. A systematic review of treatment options for dermal photosensitivity in erythropoietic protoporphyria. Cell Mol Biol (Noisy-le-grand) 2009, 55:84-97.
9. Wiklund I. Assessment of patient-reported outcomes in clinical trials: the example of health-related quality of life. Fundam Clin Pharmacol 2004, 18:351-363. 10.1111/j.1472-8206.2004.00234.x, 15147288.
10. Stang PE, Pham SV, Kinchen K, Raff SB, Mussen F, Gondek K. The identification of benefit in medical intervention: an overview and suggestions for process. Am J Ther 2008, 15:495-503. 10.1097/MJT.0b013e31816b8fff, 18806527.
11. Revicki DA, Gnanasakthy A, Weinfurt K. Documenting the rationale and psychometric characteristics of patient reported outcomes for labeling and promotional claims: the PRO Evidence Dossier. Qual Life Res 2007, 16:717-723. 10.1007/s11136-006-9153-5, 17268927.
12. Revicki DA, Osoba D, Fairclough D, Barofsky I, Berzon R, Leidy NK, Rothman M. Recommendations on health-related quality of life research to support labeling and promotional claims in the United States. Qual Life Res 2000, 9:887-900. 10.1023/A:1008996223999, 11284208.
13. Revicki DA, Gnanasakthy A, Weinfurt K. Documenting the rationale and psychometric characteristics of patient reported outcomes for labeling and promotional claims: the PRO Evidence Dossier. Qual Life Res 2007, 16:717-723. 10.1007/s11136-006-9153-5, 17268927.
14. Lohr KN, Aaronson NK, Alonso J, Burnam MA, Patrick DL, Perrin EB, Roberts JS. Evaluating quality-of-life and health status instruments: development of scientific review criteria. Clin Ther 1996, 18:979-992. 10.1016/S0149-2918(96)80054-3, 8930436.
15. Guyatt GH, Veldhuyzen Van Zanten SJ, Feeny DH, Patrick DL. Measuring quality of life in clinical trials: a taxonomy and review. CMAJ 1989, 140:1441-1448. 1269981, 2655856.
16. Willke RJ, Burke LB, Erickson P. Measuring treatment impact: a review of patient-reported outcomes and other efficacy endpoints in approved product labels. Control Clin Trials 2004, 25:535-552. 10.1016/j.cct.2004.09.003, 15588741.
17. Basra MK, Fenech R, Gatt RM, Salek MS, Finlay AY. The Dermatology Life Quality Index 1994-2007: a comprehensive review of validation data and clinical results. Br J Dermatol 2008, 159:997-1035.
18. Revicki DA, Gnanasakthy A, Weinfurt K. Documenting the rationale and psychometric characteristics of patient reported outcomes for labeling and promotional claims: the PRO Evidence Dossier. Qual Life Res 2007, 16:717-723. 10.1007/s11136-006-9153-5, 17268927.
19. Leidy NK, Revicki DA, Geneste B. Recommendations for evaluating the validity of quality of life claims for labeling and promotion. Value Health 1999, 2:113-127. 10.1046/j.1524-4733.1999.02210.x, 16674343.
20. Revicki DA, Gnanasakthy A, Weinfurt K. Documenting the rationale and psychometric characteristics of patient reported outcomes for labeling and promotional claims: the PRO Evidence Dossier. Qual Life Res 2007, 16:717-723. 10.1007/s11136-006-9153-5, 17268927.
21. Atkinson MJ, Lennox RD. Extending basic principles of measurement models to the design and validation of Patient Reported Outcomes. Health Qual Life Outcomes 2006, 4:65. 10.1186/1477-7525-4-65, 1590011, 16995937.
22. Revicki DA, Cella D, Hays RD, Sloan JA, Lenderking WR, Aaronson NK. Responsiveness and minimal important differences for patient reported outcomes. Health Qual Life Outcomes 2006, 4:70. 10.1186/1477-7525-4-70, 1586195, 17005038.
23. Revicki D, Hays RD, Cella D, Sloan J. Recommended methods for determining responsiveness and minimally important differences for patient-reported outcomes. J Clin Epidemiol 2008, 61:102-109. 10.1016/j.jclinepi.2007.03.012, 18177782.
24. Revicki D, Hays RD, Cella D, Sloan J. Recommended methods for determining responsiveness and minimally important differences for patient-reported outcomes. J Clin Epidemiol 2008, 61:102-109. 10.1016/j.jclinepi.2007.03.012, 18177782.
25. Wiklund I. Assessment of patient-reported outcomes in clinical trials: the example of health-related quality of life. Fundam Clin Pharmacol 2004, 18:351-363. 10.1111/j.1472-8206.2004.00234.x, 15147288.
26. Ebel RL. Estimation of the reliability of ratings. Psychometrika 1951, 16:407-424.
27. Mathews-Roth MM, Roberts JE. Treatment of Erythropoietic Protoporphyria With N-Acetylcysteine-Reply. Arch Dermatol 1995, 131:355. 10.1001/archderm.131.3.355, 7887672.
28. Sarkany RP. Erythropoietic protoporphyria (EPP) at 40. Where are we now?. Photodermatol Photoimmunol Photomed 2002, 18:147-152. 10.1034/j.1600-0781.2002.00708.x, 12207680.
29. Leidy NK, Revicki DA, Geneste B. Recommendations for evaluating the validity of quality of life claims for labeling and promotion. Value Health 1999, 2:113-127. 10.1046/j.1524-4733.1999.02210.x, 16674343.
30. Collins P, Ferguson J. Narrow-band UVB (TL-01) phototherapy: an effective preventative treatment for the photodermatoses. Br J Dermatol 1995, 132:956-963.
31. Warren LJ, George S. Erythropoietic protoporphyria treated with narrow-band (TL-01) UVB phototherapy. Australas J Dermatol 1998, 39:179-182. 10.1111/j.1440-0960.1998.tb01278.x, 9737047.
32. Harms J, Lautenschlager S, Minder CE, Minder EI. An alpha-melanocyte-stimulating hormone analogue in erythropoietic protoporphyria. N Engl J Med 2009, 360:306-307. 10.1056/NEJMc0805682, 19144952.
33. Harms JH, Lautenschlager S, Minder CE, Minder EI. Mitigating photosensitivity of erythropoietic protoporphyria patients by an agonistic analog of alpha-melanocyte stimulating hormone. Photochem Photobiol 2009, 85:1434-1439. 10.1111/j.1751-1097.2009.00595.x, 19656325.
34. Passing H, Bablok W. A New Biometrical Procedure for Testing the Equality of Measurements from Two Different Analytical Methods. J Clin Chem Biochem 1983, 21:709-720.